CD200 and pneumonia: In particular, the mitochondrial respiratory chain (MRC; See Figure 1 for the structure of MRC) is a target of the MRC-inhibitory drug atovaquone (ATQ; hydroxy-1,4-naphthoquinone) for control of the infections of fungi, such as Pneumocystis jirovecii (pneumonia) [5].